Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.
| Revenue (Most Recent Fiscal Year) | $291.85M |
| Net Income (Most Recent Fiscal Year) | $-54.84M |
| PE Ratio (Current Year Earnings Estimate) | 45.81 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 73.57 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 60.60 |
| Pre-Tax Margin (Trailing 12 Months) | 0.19% |
| Net Margin (Trailing 12 Months) | 0.19% |
| Return on Equity (Trailing 12 Months) | -5.33% |
| Return on Assets (Trailing 12 Months) | 0.16% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.19 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.35 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 16.10 |
| Inventory Turnover (Trailing 12 Months) | 0.66 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.20 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $0.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 172.43M |
| Free Float | 161.28M |
| Market Capitalization | $1.05B |
| Average Volume (Last 20 Days) | 2.03M |
| Beta (Past 60 Months) | 0.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.47% |
| Percentage Held By Institutions (Latest 13F Reports) | 42.75% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |